ARCHIVED - Patented Medicine Prices Review Board Canada
This page has been archived.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
2009-10
Report on Plans and Priorities
Patented Medicine Prices Review Board Canada
Supplementary Information (Tables)
Table of Contents
Sources of Non-Respendable Revenue ($ thousands)
| Program Activity | Forecast Revenue 2008–09 |
Planned Revenue 2009–10 |
Planned Revenue 2010–11 |
Planned Revenue 2011–12 |
|---|---|---|---|---|
| Compliance and enforcement of non-excessive pricing for patented medicines | 9,416.71 | - | - | - |
| Total Non-respendable Revenue | 9,416.7 | - | - | - |
1 The money reported as non-respendable revenue does not represent revenues generated by the PMPRB. This money is a result of payments made by patentees to the Government of Canada through Voluntary Compliance Undertakings (VCUs) or Board orders to offset excess revenues. The Minister may enter into agreements with any province or territory respecting the distribution to that province/territory of amounts received by the Receiver General, less any costs incurred in relation to the collection and distribution of those amounts.